  10,000 10 000 0 N/a 2024-06-01 2027-06-01 N/a 
 
In total 0 10,000 0 10,000 10 000 0 
 
* During 202 4, the CEO was awarded 10,000 PSUs in the long-term incentive program 2024/2027 . The program includes the sub -conditions that the share price must increase by at least 30 
percent over the three -year period (30 percent of the total number of PSUs), conditions relating to the company’s research and development and/or pa rtnerships (60 percent of the total 
number of PSUs), and a sustainability -related condition (10 percent of the total number of PSUs). 
 
Variable remuneration 
Criteria for payment of variable remuneration 
The variable remuneration may consist of bonuses for senior executives in the form of cash, shares and/or share -related instruments in BioArctic 
AB. Variable remuneration shall relate to the outcome of BioArctic's goals and strategies and shall be based on predetermined and measurable 
criteria designed to promote long -term value creation. The criteria for var tributions will not be made in relation to the 
milestone remuneration. 
In 202 4, no milestones under BioArctic's reward programs were achieved and no milestone payments in accordance with the reward programs 
were paid out. 
 
Variable remuneration to senior executives 
The board has also, in accordance with the remuneration guidelines, decided that senior executives in the company shall be ab le to receive 
variable cash remuneration based on predetermined and measurable criteria. The criteria for receiving variable remune ration are linked to 
collective and individual business goals that are determined individually for each executive. 
In 202 4, the criteria for variable remuneration to the CEO have been linked to operational goals regarding, among other things, supporting the 
regulatory process for lecanemab, preclinical work with exidavnemab (BAN0805) , continuing to develop new research collaborations and 
expanding the company’s organization to be able to achieve the company’ achieve the company’s goals . 
The table below shows the outcome of the CEO's fulfilment of the criteria for variable remuneration for the year 2024 and the variable cash 
remuneration for the year 202 4.

9 (8) 
 Performance of the CEO during the reported financial year: variable cash remuneration 
Name of director 
(position) 1 
Description of the criteria related to the remuneration 
component 2 
Relative weighting of the performance 
criteria 3 
a) Measured performance and 
b) actual award/ remuneration outcome1 
 
Gunilla Osswald 
(CEO) Individual operational goals 202 4 60% a) 100 % 
b) 1,040 kSEK 
 Company operational goals 202 4 40% a) 100 % 
b) 693 kSEK 
 
1 Refers to the bonus for the 202 4 financial year that will be paid out in 202 5 
 
 
Comparative information on the change of remuneration and company performance 
Change of remuneration and company performance over the last five reported financial years (RFY) (kSEK) 
 2020 vs 2019 2021 vs 2020 2022 vs 2021 2023 vs 2022 20 salaries were paid out related to achieved milestones, which explains the increase of remuneration to the CEO as well as the average 
remuneration in 2022 compared with 2021 . In 2023, the board offered the CEO a repurchase of 60,000 vested employee stock options for a cash 
consideration on market terms. The CEO accepted the offer. The total consideration amounted to SEK 13,622,400, which explains the increase 
of remuneration to the CEO in 2023 compared with 2022 and the decrease of remuneration to the CEO in 2024 compared with 2023 . 
BioArctic's revenues consist of milestone remuneration, remuneration from research agreements and research grants. Due to the nature of the 
business, there can be large fluctuations between revenues and operating profit for different periods when revenues from milestone remuneration 
are reported at the time when the performance commitments are met. 
 
Please note that the English version of this document is a translation which has been made for conve